Vargatef (Ovarian Cancer) – Analysis and Forecasts to 2020 - GlobalData's pharmaceuticals report, "Vargatef (Ovarian Cancer) - Analysis and Forecats to 2020" provides Vargatef sales forecasts for the US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2017-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Report Scope

- Therapy area profile including patient population for the US and EU5
- Analysis and review of Vargatef including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Vargatef including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts for 2017-2020 for Vargatef in the US and EU5

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Keywords

Vargatef, BIBF1120, ovarian cancer, Boeringer Ingelheim, triple angiokinase inhibitor, vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), first line treatment of locally advanced, metastatic ovarian cancer, advanced non-small cell lung cancer (NSCLC), prostate cancer, colorectal cancer, sales forecast, phase III/pipeline, competitors to vargatef hycamtin, Doxil, paclitaxel, oral triple angiokinase inhibitor

Click for Report details:Vargatef (Ovarian Cancer) – Analysis and Forecasts to 2020